Clinical, molecular, and immunological responses to pembrolizumab treatment of synchronous melanoma and acute myeloid leukemia

Pembrolizumab treatment of melanoma and concomitant sAML resulted in a significant platelet response and clearance of IDH1 mutation. Pembrolizumab therapy and response was associated with an increased PD-L1 expression on acute myeloid leukemia blasts and T cells.

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Kubasch, Anne Sophie, Wehner, Rebekka, Bazzurri, Serena, Tunger, Antje, Stasik, Sebastian, Garzarolli, Marlene, Meinel, Jörn, Baretton, Gustavo, Meier, Friedegund, Thiede, Christian, Schmitz, Marc, Platzbecker, Uwe
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2018
Assuntos:
Exceptional Case Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5998917/
https://ncbi.nlm.nih.gov/pubmed/29844203
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2017014811
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados